|
KMID : 0620920230550091996
|
|
Experimental & Molecular Medicine
2023 Volume.55 No. 9 p.1996 ~ p.2004
|
|
|
Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment
|
|
Yang Ju-Won
Bae Hyun-Su
|
|
|
Abstract
|
|
|
|
Within the tumor microenvironment (TME), regulatory T cells (Tregs) play a key role in suppressing anticancer immune responses; therefore, various strategies targeting Tregs are becoming important for tumor therapy. To prevent the side effects of nonspecific Treg depletion, such as immunotherapy-related adverse events (irAEs), therapeutic strategies that specifically target Tregs in the TME are being investigated. Tumor-targeting drug conjugates are efficient drugs in which a cytotoxic payload is assembled into a carrier that binds Tregs via a linker. By allowing the drug to act selectively on target cells, this approach has the advantage of increasing the therapeutic effect and minimizing the side effects of immunotherapy. Antibody?drug conjugates, immunotoxins, peptide?drug conjugates, and small interfering RNA conjugates are being developed as Treg-targeting drug conjugates. In this review, we discuss key themes and recent advances in drug conjugates targeting Tregs in the TME, as well as future design strategies for successful use of drug conjugates for Treg targeting in immunotherapy.
|
|
|
KEYWORD
|
|
|
Cancer therapy, Tumour immunology
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|